MDXG

MiMedx Group, Inc. is a placental biologics company focused on providing a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. It also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.

Wall Street analysts forecast MDXG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDXG is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

MiMedx Group Inc revenue for the last quarter amounts to 113.73M USD, increased 35.30 % YoY.

MiMedx Group Inc. EPS for the last quarter amounts to 0.11 USD, increased 120.00 % YoY.

MiMedx Group Inc (MDXG) has 837 emplpoyees as of December 16 2025.

Today MDXG has the market capitalization of 1.05B USD.